23andMe Holding released a new genetic Bipolar Disorder report for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition. Bipolar disorder is a mental health condition that can cause extreme and unusual shifts in mood, energy, behavior and activity, ranging from highs to lows. 23andMe’s new report is based on a statistical model known as polygenic risk score, developed by 23andMe through its proprietary research database. The Bipolar Disorder PRS report calculates the likelihood of an individual being diagnosed with the condition based on thousands of different genetic variants, as well as a customer’s genetic ancestry and birth sex.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ME:
- 23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
- 23andMe Reveals Promising Data for New Antibody at ASCO
- 23andMe announces preliminary Phase 2 safety results for 23ME-00610 at ASCO
- 23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
- Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history